Table 2 Comparison of IPSS between group 1 and 2

From: Efficacy and safety of combination therapy with mirodenafil and α1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study

 

IPSS

IPSS difference a

P-value

 

V1

V2

V3

 

V1 vs V2 b

V1 vs V3 b

Group 1 vs 2 c

Group 1 (n=35)

16.06±6.69

11.03±5.18

8.91±4.51

7.14±4.94

<0.001

<0.001

0.401

Group 2 (n=38)

15.18±8.75

11.53±6.33

9.11±5.21

6.08±5.75

<0.001

<0.001

 
  1. Group 1: those with difference of IIEF-5d⩽8 between V3 and V1, group 2: those with difference of IIEF-5>8 between V3 and V1.
  2. Abbreviations: IIEF, international index of erectile function; IPSS, international prostate symptom score; Qmax, peak urine flow rate.
  3. aDifference of IPSS between V1 and V3.
  4. bStudent's paired t-test.
  5. cStudent's independent t-test.
  6. dFive-item version of the IIEF.
Back to article page